Virus Augmentation of The Antigenicity of Tumor Cell

Austin, Faye C.; Boone, Charles W.

doi:10.1016/s0065-230x(08)60900-8

Cited by 62 publications

(26 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, we tested viral replication in embryonated chicken eggs. When infection was performed with the standard NDV, pre-diluted 1:10 4 , the allantois fluid harvested after appropriate incubation had a hemagglutinating titer of 2 9 . When the NDV-Fo preparation was tested in parallel over a wide dose range spanning 5 log 10 scales no virus activity could be recovered from any of the allantois fluids harvested.…”

Section: Cells Of the Carcinoma Cell Line Nit16 Were Infected By 32 Hmentioning

confidence: 99%

See 1 more Smart Citation

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

et al. 1999

View full text Add to dashboard Cite

Section: Cells Of the Carcinoma Cell Line Nit16 Were Infected By 32 Hmentioning

confidence: 99%

“…Virus augmentation of the antigenicity of cell extracts had been observed in several model systems. 9 Impressive long-term survival benefits were reported from two studies involving 83 stage 2 malignant melanoma patients with a 5 year survival rate of 69%. 10,11 The usual 5 year survival of such operated patients would have been only 17%.…”

Section: Introductionmentioning

confidence: 99%

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

et al. 1999

View full text Add to dashboard Cite

“…A very effective approach consisted in the introduction of viral antigens (VA), for instance via infection of tumor cells by viruses, such as influenza (Lindenmann, 1974;Boone et al, 1971) or Newcastle disease virus (Beverley et al, 1973;Cassel and Garrett, 1965) which mature at the tumor cell surface. When intact tumor cells infected by non-lytic viruses were used (Kobayashi et al, 1970(Kobayashi et al, , 1975Kobayashi, 1979) the increase in immunogenicity was much stronger than that obtained with tumor cells infected by oncolytic virus (Lindenmann and Klein, 1967;Lindenmann, 1970) or with cell-free homogenates of virus-infected tumor cells (Griffith et al, 1975;Axler and Girardi, 1970;Austin and Boone, 1979). For this reason we chose for our studies a nonlytic virus.…”

mentioning

confidence: 99%

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

Heicappell

Schirrmacher

Hoegen

et al. 1986

Intl Journal of Cancer

103

View full text Add to dashboard Cite

Effective anti-metastatic therapy was achieved in a mouse tumor model by combining surgery with post-operative immunotherapy using virus-modified autologous tumor cells. No therapeutic effect was observed when using for immunotherapy the nonmodified autologous tumor ESb, which is only weakly immunogenic and highly metastatic. The viral modification was achieved by infecting the tumor with an avirulent strain of Newcastle disease virus (NDV), which led to expression of viral antigens and to an increase in the tumor cells' immunogenicity. Parameters which were of decisive influence for success or failure of therapy were the time of operation of the primary tumor and the dose of virus which was admixed to a standard dose of irradiated tumor cells. There was a low dose optimum of NDV at about 100 hemagglutinating units per 25 X 10(6) tumor cells. The therapeutic effect observed was less pronounced if the virus was given separately from the tumor cells. Post-operative immunotherapy with NDV-modified tumor cells had the following therapeutic effects: (1) disappearance of micrometastases from visceral organs as ascertained by a sensitive bioassay; (2) life prolongation in virtually all animals when compared to controls (operated only); (3) cures in about 50% of the treated animals. The possible mechanism of this therapeutic effect and its potential for clinical application are discussed.

show abstract

“…Lysate Vaccines Viral lysates. The ability of a virus to induce longlasting antitumor immunity via viral-induced oncolysis was first demonstrated in an animal model [45]. Human studies with lysates induced by a wide variety of viruses, including vaccinia [46], suggested a possible therapeutic role for viral lysates.…”

Section: Whole-cell Polyvalent Vaccinesmentioning

confidence: 99%